APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Chronic Heart Failure (CHF) Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Chronic Heart Failure (CHF) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173977940331 December 2025197 pages

Choose your research edition.

Industry ResearchChronic Heart Failure (CHF) Drugs Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Chronic Heart Failure (CHF) Drugs Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Chronic Heart Failure (CHF) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chronic Heart Failure (CHF) Drugs Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Chronic Heart Failure (CHF) Drugs Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Chronic Heart Failure (CHF) Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Chronic Heart Failure (CHF) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Chronic Heart Failure (CHF) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Chronic Heart Failure (CHF) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Chronic Heart Failure (CHF) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Chronic Heart Failure (CHF) Drugs include Abbott, Johnson & Johnson, Merck, Pfizer, Symplmed Pharmaceuticals, Stanley Pharmaceuticals, Novartis International AG, New Haven Pharmaceuticals, Inc. and GlaxoSmithKline plc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Chronic Heart Failure (CHF) Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Chronic Heart Failure (CHF) Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Chronic Heart Failure (CHF) Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Chronic Heart Failure (CHF) Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Chronic Heart Failure (CHF) Drugs Segment by Company

Abbott

Johnson & Johnson

Merck

Pfizer

Symplmed Pharmaceuticals

Stanley Pharmaceuticals

Novartis International AG

New Haven Pharmaceuticals, Inc.

GlaxoSmithKline plc

Bristol-Myers Squibb Company

Biovail Corporation

Chronic Heart Failure (CHF) Drugs Segment by Type

Anti-clotting (Aspirin)

Anticoagulant Medicines (Warfarin)

Antiplatelet Medicines (Clopidogrel, Prasugrel, and Ticagrelor)

Diuretics

Statins

Blood Pressure Maintaining Agents (Angiotensin Converting Enzyme (ACE) Inhibitors)

Nitrates

Angiotensin II Receptor Blockers (ARB)

Chronic Heart Failure (CHF) Drugs Segment by Application

Hospital

Clinic

Others

Chronic Heart Failure (CHF) Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chronic Heart Failure (CHF) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chronic Heart Failure (CHF) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chronic Heart Failure (CHF) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Chronic Heart Failure (CHF) Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Chronic Heart Failure (CHF) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Chronic Heart Failure (CHF) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Chronic Heart Failure (CHF) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Chronic Heart Failure (CHF) Drugs Industry Trends Table 2. Chronic Heart Failure (CHF) Drugs Industry Drivers Table 3. Chronic Heart Failure (CHF) Drugs Industry Opportunities and Challenges Table 4. Chronic Heart Failure (CHF) Drugs Industry Restraints Table 5. Global Chronic Heart Failure (CHF) Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Chronic Heart Failure (CHF) Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Chronic Heart Failure (CHF) Drugs Sales by Manufacturers (Kg) & (2021-2026) Table 8. Global Chronic Heart Failure (CHF) Drugs Sales Market Share by Manufacturers Table 9. Global Chronic Heart Failure (CHF) Drugs Average Sales Price (US$/g) of Manufacturers (2021-2026) Table 10. Global Chronic Heart Failure (CHF) Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Chronic Heart Failure (CHF) Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Chronic Heart Failure (CHF) Drugs Manufacturers, Product Type & Application Table 13. Global Chronic Heart Failure (CHF) Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Chronic Heart Failure (CHF) Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Anti-clotting (Aspirin) Table 17. Major Manufacturers of Anticoagulant Medicines (Warfarin) Table 18. Major Manufacturers of Antiplatelet Medicines (Clopidogrel, Prasugrel, and Ticagrelor) Table 19. Major Manufacturers of Diuretics Table 20. Major Manufacturers of Statins Table 21. Major Manufacturers of Blood Pressure Maintaining Agents (Angiotensin Converting Enzyme (ACE) Inhibitors) Table 22. Major Manufacturers of Nitrates Table 23. Major Manufacturers of Angiotensin II Receptor Blockers (ARB) Table 24. Global Chronic Heart Failure (CHF) Drugs Sales by Type 2021 VS 2025 VS 2032 (Kg) Table 25. Global Chronic Heart Failure (CHF) Drugs Sales by Type (2021-2026) & (Kg) Table 26. Global Chronic Heart Failure (CHF) Drugs Sales by Type (2027-2032) & (Kg) Table 27. Global Chronic Heart Failure (CHF) Drugs Sales Market Share by Type (2021-2026) Table 28. Global Chronic Heart Failure (CHF) Drugs Sales Market Share by Type (2027-2032) Table 29. Global Chronic Heart Failure (CHF) Drugs Revenue by Type 2021 VS 2025 VS 2032 (Kg) Table 30. Global Chronic Heart Failure (CHF) Drugs Revenue by Type (2021-2026) & (Kg) Table 31. Global Chronic Heart Failure (CHF) Drugs Revenue by Type (2027-2032) & (Kg) Table 32. Global Chronic Heart Failure (CHF) Drugs Revenue Market Share by Type (2021-2026) Table 33. Global Chronic Heart Failure (CHF) Drugs Revenue Market Share by Type (2027-2032) Table 34. Major Manufacturers of Hospital Table 35. Major Manufacturers of Clinic Table 36. Major Manufacturers of Others Table 37. Global Chronic Heart Failure (CHF) Drugs Sales by Application 2021 VS 2025 VS 2032 (Kg) Table 38. Global Chronic Heart Failure (CHF) Drugs Sales by Application (2021-2026) & (Kg) Table 39. Global Chronic Heart Failure (CHF) Drugs Sales by Application (2027-2032) & (Kg) Table 40. Global Chronic Heart Failure (CHF) Drugs Sales Market Share by Application (2021-2026) Table 41. Global Chronic Heart Failure (CHF) Drugs Sales Market Share by Application (2027-2032) Table 42. Global Chronic Heart Failure (CHF) Drugs Revenue by Application 2021 VS 2025 VS 2032 (Kg) Table 43. Global Chronic Heart Failure (CHF) Drugs Revenue by Application (2021-2026) & (Kg) Table 44. Global Chronic Heart Failure (CHF) Drugs Revenue by Application (2027-2032) & (Kg) Table 45. Global Chronic Heart Failure (CHF) Drugs Revenue Market Share by Application (2021-2026) Table 46. Global Chronic Heart Failure (CHF) Drugs Revenue Market Share by Application (2027-2032) Table 47. Global Chronic Heart Failure (CHF) Drugs Sales by Region: 2021 VS 2025 VS 2032 (Kg) Table 48. Global Chronic Heart Failure (CHF) Drugs Sales by Region (2021-2026) & (Kg) Table 49. Global Chronic Heart Failure (CHF) Drugs Sales Market Share by Region (2021-2026) Table 50. Global Chronic Heart Failure (CHF) Drugs Sales Forecasted by Region (2027-2032) & (Kg) Table 51. Global Chronic Heart Failure (CHF) Drugs Sales Forecasted Market Share by Region (2027-2032) Table 52. North America Chronic Heart Failure (CHF) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Kg) Table 53. North America Chronic Heart Failure (CHF) Drugs Sales by Country (2021-2026) & (Kg) Table 54. North America Chronic Heart Failure (CHF) Drugs Sales by Country (2027-2032) & (Kg) Table 55. Europe Chronic Heart Failure (CHF) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Kg) Table 56. Europe Chronic Heart Failure (CHF) Drugs Sales by Country (2021-2026) & (Kg) Table 57. Europe Chronic Heart Failure (CHF) Drugs Sales by Country (2027-2032) & (Kg) Table 58. Asia Pacific Chronic Heart Failure (CHF) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Kg) Table 59. Asia Pacific Chronic Heart Failure (CHF) Drugs Sales by Country (2021-2026) & (Kg) Table 60. Asia Pacific Chronic Heart Failure (CHF) Drugs Sales by Country (2027-2032) & (Kg) Table 61. South America, Middle East and Africa Chronic Heart Failure (CHF) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Kg) Table 62. South America, Middle East and Africa Chronic Heart Failure (CHF) Drugs Sales by Country (2021-2026) & (Kg) Table 63. South America, Middle East and Africa Chronic Heart Failure (CHF) Drugs Sales by Country (2027-2032) & (Kg) Table 64. Global Chronic Heart Failure (CHF) Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 65. Global Chronic Heart Failure (CHF) Drugs Revenue by Region (2021-2026) & (US$ Million) Table 66. Global Chronic Heart Failure (CHF) Drugs Revenue by Region (2027-2032) & (US$ Million) Table 67. Global Chronic Heart Failure (CHF) Drugs Revenue Market Share by Region (2021-2026) Table 68. Global Chronic Heart Failure (CHF) Drugs Revenue Market Share by Region (2027-2032) Table 69. Abbott Company Information Table 70. Abbott Business Overview Table 71. Abbott Chronic Heart Failure (CHF) Drugs Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Abbott Chronic Heart Failure (CHF) Drugs Product Portfolio Table 73. Abbott Recent Development Table 74. Johnson & Johnson Company Information Table 75. Johnson & Johnson Business Overview Table 76. Johnson & Johnson Chronic Heart Failure (CHF) Drugs Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Johnson & Johnson Chronic Heart Failure (CHF) Drugs Product Portfolio Table 78. Johnson & Johnson Recent Development Table 79. Merck Company Information Table 80. Merck Business Overview Table 81. Merck Chronic Heart Failure (CHF) Drugs Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Merck Chronic Heart Failure (CHF) Drugs Product Portfolio Table 83. Merck Recent Development Table 84. Pfizer Company Information Table 85. Pfizer Business Overview Table 86. Pfizer Chronic Heart Failure (CHF) Drugs Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Pfizer Chronic Heart Failure (CHF) Drugs Product Portfolio Table 88. Pfizer Recent Development Table 89. Symplmed Pharmaceuticals Company Information Table 90. Symplmed Pharmaceuticals Business Overview Table 91. Symplmed Pharmaceuticals Chronic Heart Failure (CHF) Drugs Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Symplmed Pharmaceuticals Chronic Heart Failure (CHF) Drugs Product Portfolio Table 93. Symplmed Pharmaceuticals Recent Development Table 94. Stanley Pharmaceuticals Company Information Table 95. Stanley Pharmaceuticals Business Overview Table 96. Stanley Pharmaceuticals Chronic Heart Failure (CHF) Drugs Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Stanley Pharmaceuticals Chronic Heart Failure (CHF) Drugs Product Portfolio Table 98. Stanley Pharmaceuticals Recent Development Table 99. Novartis International AG Company Information Table 100. Novartis International AG Business Overview Table 101. Novartis International AG Chronic Heart Failure (CHF) Drugs Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Novartis International AG Chronic Heart Failure (CHF) Drugs Product Portfolio Table 103. Novartis International AG Recent Development Table 104. New Haven Pharmaceuticals, Inc. Company Information Table 105. New Haven Pharmaceuticals, Inc. Business Overview Table 106. New Haven Pharmaceuticals, Inc. Chronic Heart Failure (CHF) Drugs Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. New Haven Pharmaceuticals, Inc. Chronic Heart Failure (CHF) Drugs Product Portfolio Table 108. New Haven Pharmaceuticals, Inc. Recent Development Table 109. GlaxoSmithKline plc Company Information Table 110. GlaxoSmithKline plc Business Overview Table 111. GlaxoSmithKline plc Chronic Heart Failure (CHF) Drugs Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. GlaxoSmithKline plc Chronic Heart Failure (CHF) Drugs Product Portfolio Table 113. GlaxoSmithKline plc Recent Development Table 114. Bristol-Myers Squibb Company Company Information Table 115. Bristol-Myers Squibb Company Business Overview Table 116. Bristol-Myers Squibb Company Chronic Heart Failure (CHF) Drugs Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Bristol-Myers Squibb Company Chronic Heart Failure (CHF) Drugs Product Portfolio Table 118. Bristol-Myers Squibb Company Recent Development Table 119. Biovail Corporation Company Information Table 120. Biovail Corporation Business Overview Table 121. Biovail Corporation Chronic Heart Failure (CHF) Drugs Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Biovail Corporation Chronic Heart Failure (CHF) Drugs Product Portfolio Table 123. Biovail Corporation Recent Development Table 124. Key Raw Materials Table 125. Raw Materials Key Suppliers Table 126. Chronic Heart Failure (CHF) Drugs Distributors List Table 127. Chronic Heart Failure (CHF) Drugs Customers List Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. Chronic Heart Failure (CHF) Drugs Product Image Figure 2. Global Chronic Heart Failure (CHF) Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Chronic Heart Failure (CHF) Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Chronic Heart Failure (CHF) Drugs Sales (2021-2032) & (Kg) Figure 5. Global Chronic Heart Failure (CHF) Drugs Average Price (US$/g) & (2021-2032) Figure 6. Global Top 5 and 10 Chronic Heart Failure (CHF) Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Anti-clotting (Aspirin) Image Figure 9. Anticoagulant Medicines (Warfarin) Image Figure 10. Antiplatelet Medicines (Clopidogrel, Prasugrel, and Ticagrelor) Image Figure 11. Diuretics Image Figure 12. Statins Image Figure 13. Blood Pressure Maintaining Agents (Angiotensin Converting Enzyme (ACE) Inhibitors) Image Figure 14. Nitrates Image Figure 15. Angiotensin II Receptor Blockers (ARB) Image Figure 16. Global Chronic Heart Failure (CHF) Drugs Sales by Type (2021 VS 2025 VS 2032) & (Kg) Figure 17. Global Chronic Heart Failure (CHF) Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 18. Global Chronic Heart Failure (CHF) Drugs Sales Market Share by Type (2021-2032) Figure 19. Global Chronic Heart Failure (CHF) Drugs Revenue by Type (2021 VS 2025 VS 2032) & (Kg) Figure 20. Global Chronic Heart Failure (CHF) Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Chronic Heart Failure (CHF) Drugs Revenue Market Share by Type (2021-2032) Figure 22. Hospital Image Figure 23. Clinic Image Figure 24. Others Image Figure 25. Global Chronic Heart Failure (CHF) Drugs Sales by Application (2021 VS 2025 VS 2032) & (Kg) Figure 26. Global Chronic Heart Failure (CHF) Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 27. Global Chronic Heart Failure (CHF) Drugs Sales Market Share by Application (2021-2032) Figure 28. Global Chronic Heart Failure (CHF) Drugs Revenue by Application (2021 VS 2025 VS 2032) & (Kg) Figure 29. Global Chronic Heart Failure (CHF) Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 30. Global Chronic Heart Failure (CHF) Drugs Revenue Market Share by Application (2021-2032) Figure 31. North America Chronic Heart Failure (CHF) Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 32. North America Chronic Heart Failure (CHF) Drugs Sales Market Share by Country (2021-2032) Figure 33. U.S. Chronic Heart Failure (CHF) Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 34. Canada Chronic Heart Failure (CHF) Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 35. Mexico Chronic Heart Failure (CHF) Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 36. Europe Chronic Heart Failure (CHF) Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 37. Europe Chronic Heart Failure (CHF) Drugs Sales Market Share by Country (2021-2032) Figure 38. Germany Chronic Heart Failure (CHF) Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 39. France Chronic Heart Failure (CHF) Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 40. U.K. Chronic Heart Failure (CHF) Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 41. Italy Chronic Heart Failure (CHF) Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 42. Netherlands Chronic Heart Failure (CHF) Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 43. Asia Pacific Chronic Heart Failure (CHF) Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 44. Asia Pacific Chronic Heart Failure (CHF) Drugs Sales Market Share by Country (2021-2032) Figure 45. China Chronic Heart Failure (CHF) Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 46. Japan Chronic Heart Failure (CHF) Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 47. South Korea Chronic Heart Failure (CHF) Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 48. Southeast Asia Chronic Heart Failure (CHF) Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 49. India Chronic Heart Failure (CHF) Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 50. Australia Chronic Heart Failure (CHF) Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 51. South America, Middle East and Africa Chronic Heart Failure (CHF) Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 52. South America, Middle East and Africa Chronic Heart Failure (CHF) Drugs Sales Market Share by Country (2021-2032) Figure 53. Brazil Chronic Heart Failure (CHF) Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 54. South Africa Chronic Heart Failure (CHF) Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 55. Saudi Arabia Chronic Heart Failure (CHF) Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 56. Turkey Chronic Heart Failure (CHF) Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 57. Argentina Chronic Heart Failure (CHF) Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 58. UAE Chronic Heart Failure (CHF) Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 59. Egypt Chronic Heart Failure (CHF) Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 60. Chile Chronic Heart Failure (CHF) Drugs Sales and Growth Rate (2021-2032) & (Kg) Figure 61. Global Chronic Heart Failure (CHF) Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Global Chronic Heart Failure (CHF) Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 63. North America Chronic Heart Failure (CHF) Drugs Revenue (2021-2032) & (US$ Million) Figure 64. North America Chronic Heart Failure (CHF) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Europe Chronic Heart Failure (CHF) Drugs Revenue (2021-2032) & (US$ Million) Figure 66. Europe Chronic Heart Failure (CHF) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Asia-Pacific Chronic Heart Failure (CHF) Drugs Revenue (2021-2032) & (US$ Million) Figure 68. Asia-Pacific Chronic Heart Failure (CHF) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. South America, Middle East and Africa Chronic Heart Failure (CHF) Drugs Revenue (2021-2032) & (US$ Million) Figure 70. South America, Middle East and Africa Chronic Heart Failure (CHF) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 71. Chronic Heart Failure (CHF) Drugs Value Chain Figure 72. Manufacturing Cost Structure Figure 73. Chronic Heart Failure (CHF) Drugs Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • Anti-clotting (Aspirin)
  • Anticoagulant Medicines (Warfarin)
  • Antiplatelet Medicines (Clopidogrel, Prasugrel, and Ticagrelor)
  • Diuretics
  • Statins
  • Blood Pressure Maintaining Agents (Angiotensin Converting Enzyme (ACE) Inhibitors)
  • Nitrates
  • Angiotensin II Receptor Blockers (ARB)
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Abbott
  • Johnson & Johnson
  • Merck
  • Pfizer
  • Symplmed Pharmaceuticals
  • Stanley Pharmaceuticals
  • Novartis International AG
  • New Haven Pharmaceuticals, Inc.
  • GlaxoSmithKline plc
  • Bristol-Myers Squibb Company
  • Biovail Corporation

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Chronic Heart Failure (CHF) Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Chronic Heart Failure (CHF) Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Chronic Heart Failure (CHF) Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Chronic Heart Failure (CHF) Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Chronic Heart Failure (CHF) Drugs Market Dynamics
  1. 2.1 Chronic Heart Failure (CHF) Drugs Industry Trends
  2. 2.2 Chronic Heart Failure (CHF) Drugs Industry Drivers
  3. 2.3 Chronic Heart Failure (CHF) Drugs Industry Opportunities and Challenges
  4. 2.4 Chronic Heart Failure (CHF) Drugs Industry Restraints
3 Chronic Heart Failure (CHF) Drugs Market by Manufacturers
  1. 3.1 Global Chronic Heart Failure (CHF) Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Chronic Heart Failure (CHF) Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Chronic Heart Failure (CHF) Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Chronic Heart Failure (CHF) Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Chronic Heart Failure (CHF) Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Chronic Heart Failure (CHF) Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Chronic Heart Failure (CHF) Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Chronic Heart Failure (CHF) Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Chronic Heart Failure (CHF) Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Chronic Heart Failure (CHF) Drugs Tier 1, Tier 2, and Tier 3
4 Chronic Heart Failure (CHF) Drugs Market by Type
  1. 4.1 Chronic Heart Failure (CHF) Drugs Type Introduction
  2. 4.1.1 Anti-clotting (Aspirin)
  3. 4.1.2 Anticoagulant Medicines (Warfarin)
  4. 4.1.3 Antiplatelet Medicines (Clopidogrel, Prasugrel, and Ticagrelor)
  5. 4.1.4 Diuretics
  6. 4.1.5 Statins
  7. 4.1.6 Blood Pressure Maintaining Agents (Angiotensin Converting Enzyme (ACE) Inhibitors)
  8. 4.1.7 Nitrates
  9. 4.1.8 Angiotensin II Receptor Blockers (ARB)
  10. 4.2 Global Chronic Heart Failure (CHF) Drugs Sales by Type
  11. 4.2.1 Global Chronic Heart Failure (CHF) Drugs Sales by Type (2021 VS 2025 VS 2032)
  12. 4.2.2 Global Chronic Heart Failure (CHF) Drugs Sales by Type (2021-2032)
  13. 4.2.3 Global Chronic Heart Failure (CHF) Drugs Sales Market Share by Type (2021-2032)
  14. 4.3 Global Chronic Heart Failure (CHF) Drugs Revenue by Type
  15. 4.3.1 Global Chronic Heart Failure (CHF) Drugs Revenue by Type (2021 VS 2025 VS 2032)
  16. 4.3.2 Global Chronic Heart Failure (CHF) Drugs Revenue by Type (2021-2032)
  17. 4.3.3 Global Chronic Heart Failure (CHF) Drugs Revenue Market Share by Type (2021-2032)
5 Chronic Heart Failure (CHF) Drugs Market by Application
  1. 5.1 Chronic Heart Failure (CHF) Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Chronic Heart Failure (CHF) Drugs Sales by Application
  6. 5.2.1 Global Chronic Heart Failure (CHF) Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Chronic Heart Failure (CHF) Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global Chronic Heart Failure (CHF) Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global Chronic Heart Failure (CHF) Drugs Revenue by Application
  10. 5.3.1 Global Chronic Heart Failure (CHF) Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Chronic Heart Failure (CHF) Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global Chronic Heart Failure (CHF) Drugs Revenue Market Share by Application (2021-2032)
6 Global Chronic Heart Failure (CHF) Drugs Sales by Region
  1. 6.1 Global Chronic Heart Failure (CHF) Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Chronic Heart Failure (CHF) Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Chronic Heart Failure (CHF) Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Chronic Heart Failure (CHF) Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Chronic Heart Failure (CHF) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Chronic Heart Failure (CHF) Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Chronic Heart Failure (CHF) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Chronic Heart Failure (CHF) Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Chronic Heart Failure (CHF) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Chronic Heart Failure (CHF) Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Chronic Heart Failure (CHF) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Chronic Heart Failure (CHF) Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Chronic Heart Failure (CHF) Drugs Revenue by Region
  1. 7.1 Global Chronic Heart Failure (CHF) Drugs Revenue by Region
  2. 7.1.1 Global Chronic Heart Failure (CHF) Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Chronic Heart Failure (CHF) Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Chronic Heart Failure (CHF) Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Chronic Heart Failure (CHF) Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Chronic Heart Failure (CHF) Drugs Revenue (2021-2032)
  8. 7.2.2 North America Chronic Heart Failure (CHF) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Chronic Heart Failure (CHF) Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Chronic Heart Failure (CHF) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Chronic Heart Failure (CHF) Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Chronic Heart Failure (CHF) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Chronic Heart Failure (CHF) Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Chronic Heart Failure (CHF) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Abbott
  2. 8.1.1 Abbott Company Information
  3. 8.1.2 Abbott Business Overview
  4. 8.1.3 Abbott Chronic Heart Failure (CHF) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Abbott Chronic Heart Failure (CHF) Drugs Product Portfolio
  6. 8.1.5 Abbott Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Chronic Heart Failure (CHF) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Chronic Heart Failure (CHF) Drugs Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck Chronic Heart Failure (CHF) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck Chronic Heart Failure (CHF) Drugs Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Chronic Heart Failure (CHF) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Chronic Heart Failure (CHF) Drugs Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 Symplmed Pharmaceuticals
  26. 8.5.1 Symplmed Pharmaceuticals Company Information
  27. 8.5.2 Symplmed Pharmaceuticals Business Overview
  28. 8.5.3 Symplmed Pharmaceuticals Chronic Heart Failure (CHF) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Symplmed Pharmaceuticals Chronic Heart Failure (CHF) Drugs Product Portfolio
  30. 8.5.5 Symplmed Pharmaceuticals Recent Developments
  31. 8.6 Stanley Pharmaceuticals
  32. 8.6.1 Stanley Pharmaceuticals Company Information
  33. 8.6.2 Stanley Pharmaceuticals Business Overview
  34. 8.6.3 Stanley Pharmaceuticals Chronic Heart Failure (CHF) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Stanley Pharmaceuticals Chronic Heart Failure (CHF) Drugs Product Portfolio
  36. 8.6.5 Stanley Pharmaceuticals Recent Developments
  37. 8.7 Novartis International AG
  38. 8.7.1 Novartis International AG Company Information
  39. 8.7.2 Novartis International AG Business Overview
  40. 8.7.3 Novartis International AG Chronic Heart Failure (CHF) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Novartis International AG Chronic Heart Failure (CHF) Drugs Product Portfolio
  42. 8.7.5 Novartis International AG Recent Developments
  43. 8.8 New Haven Pharmaceuticals, Inc.
  44. 8.8.1 New Haven Pharmaceuticals, Inc. Company Information
  45. 8.8.2 New Haven Pharmaceuticals, Inc. Business Overview
  46. 8.8.3 New Haven Pharmaceuticals, Inc. Chronic Heart Failure (CHF) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 New Haven Pharmaceuticals, Inc. Chronic Heart Failure (CHF) Drugs Product Portfolio
  48. 8.8.5 New Haven Pharmaceuticals, Inc. Recent Developments
  49. 8.9 GlaxoSmithKline plc
  50. 8.9.1 GlaxoSmithKline plc Company Information
  51. 8.9.2 GlaxoSmithKline plc Business Overview
  52. 8.9.3 GlaxoSmithKline plc Chronic Heart Failure (CHF) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 GlaxoSmithKline plc Chronic Heart Failure (CHF) Drugs Product Portfolio
  54. 8.9.5 GlaxoSmithKline plc Recent Developments
  55. 8.10 Bristol-Myers Squibb Company
  56. 8.10.1 Bristol-Myers Squibb Company Company Information
  57. 8.10.2 Bristol-Myers Squibb Company Business Overview
  58. 8.10.3 Bristol-Myers Squibb Company Chronic Heart Failure (CHF) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bristol-Myers Squibb Company Chronic Heart Failure (CHF) Drugs Product Portfolio
  60. 8.10.5 Bristol-Myers Squibb Company Recent Developments
  61. 8.11 Biovail Corporation
  62. 8.11.1 Biovail Corporation Company Information
  63. 8.11.2 Biovail Corporation Business Overview
  64. 8.11.3 Biovail Corporation Chronic Heart Failure (CHF) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Biovail Corporation Chronic Heart Failure (CHF) Drugs Product Portfolio
  66. 8.11.5 Biovail Corporation Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Chronic Heart Failure (CHF) Drugs Value Chain Analysis
  2. 9.1.1 Chronic Heart Failure (CHF) Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Chronic Heart Failure (CHF) Drugs Production Mode & Process
  6. 9.2 Chronic Heart Failure (CHF) Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Chronic Heart Failure (CHF) Drugs Distributors
  9. 9.2.3 Chronic Heart Failure (CHF) Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst